Evaluation of the Effectiveness of Prophylactic LMWH by Thromboelastography

Recruiting

• Conditions: Malignancy

• Registration Number: NCT06484231
• Lead Sponsor: Ege University

Brief Summary

This study aims to evaluate the necessity and effectiveness of using low molecular weight heparin (LMWH) for prophylaxis in the postoperative period in patients who underwent lobectomy due to malignancy, using thromboelastography.Blood samples taken from the patients before low molecular weight heparin prophylaxis (preoperative), before prophylaxis in the postoperative period (postoperative day 1) and after the start of postoperative prophylaxis (postoperative day 3) will be examined by thromboelastography.

Detailed Description

General characteristics of the patients such as age, gender, presence of comorbidities, smoking, type of operation and approach applied, operation duration, TEG measurements and postoperative complication development were recorded with case forms.

Study Timeline

• Study Start: 2023-07-24
• Status Verified: 2024-06
• Study First Submitted: 2024-06-26
• Study First Submitted QC: 2024-06-26
• Last Update Submitted: 2024-06-26
• Study First Posted: 2024-07-03
• Last Update Posted: 2024-07-03
• Primary Completion: 2025-07-24
• Study Completion: 2025-07-24

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 25

Inclusion Criteria

• Patients who underwent lobectomy with thoracotomy or videothoracoscopy (VATS) due to malignancy (primary or secondary lung cancer)

Exclusion Criteria

• Patients with a known diagnosis of bleeding or coagulation disorders
• Patients receiving anticoagulant and antiplatelet therapy in the preoperative period
• Patients who developed perioperative bleeding and therefore underwent perioperative blood and blood product replacement

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
r time	24 months	'r time' value measured by thromboelastography
angle a	24 months	'angle a' value measured by thromboelastography
k time	24 months	'k time' value measured by thromboelastography
maximum amplitude (MA)	24 months	'MA' value measured by thromboelastography

Secondary Outcome Measures

Name	Time	Method
complications	24 months	development of complications

Trial Locations

Locations (1)

Ege University Faculty of Medicine; 🇹🇷 İzmir, Bornova, Turkey